JP6745873B2 - 神経変性における治療標的としての細胞外ｄｎａ - Google Patents

神経変性における治療標的としての細胞外ｄｎａ Download PDF

Info

Publication number
JP6745873B2
JP6745873B2 JP2018513264A JP2018513264A JP6745873B2 JP 6745873 B2 JP6745873 B2 JP 6745873B2 JP 2018513264 A JP2018513264 A JP 2018513264A JP 2018513264 A JP2018513264 A JP 2018513264A JP 6745873 B2 JP6745873 B2 JP 6745873B2
Authority
JP
Japan
Prior art keywords
dnase
pharmaceutical composition
composition according
disease
neurodegeneration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018513264A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018520208A5 (cg-RX-API-DMAC7.html
JP2018520208A (ja
Inventor
ドミトリエヴィッチ ゲンキン，ドミトリー
ドミトリエヴィッチ ゲンキン，ドミトリー
ヴィクトロヴィッチ テッツ，ゲオルギー
ヴィクトロヴィッチ テッツ，ゲオルギー
ヴェニアミノヴィッチ テッツ，ヴィクター
ヴェニアミノヴィッチ テッツ，ヴィクター
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2018520208A publication Critical patent/JP2018520208A/ja
Publication of JP2018520208A5 publication Critical patent/JP2018520208A5/ja
Application granted granted Critical
Publication of JP6745873B2 publication Critical patent/JP6745873B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/02—Thioester hydrolases (3.1.2)
    • C12Y301/02021—Dodecanoyl-[acyl-carrier-protein] hydrolase (3.1.2.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/21—Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
    • C12Y301/21001—Deoxyribonuclease I (3.1.21.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2018513264A 2015-05-22 2016-05-11 神経変性における治療標的としての細胞外ｄｎａ Active JP6745873B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562165255P 2015-05-22 2015-05-22
US62/165,255 2015-05-22
PCT/RU2016/000284 WO2016190780A1 (en) 2015-05-22 2016-05-11 Extracellular dna as a therapeutic target in neurodegeneration

Publications (3)

Publication Number Publication Date
JP2018520208A JP2018520208A (ja) 2018-07-26
JP2018520208A5 JP2018520208A5 (cg-RX-API-DMAC7.html) 2019-09-19
JP6745873B2 true JP6745873B2 (ja) 2020-08-26

Family

ID=57393467

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018513264A Active JP6745873B2 (ja) 2015-05-22 2016-05-11 神経変性における治療標的としての細胞外ｄｎａ

Country Status (7)

Country Link
US (1) US11701410B2 (cg-RX-API-DMAC7.html)
EP (1) EP3297657B1 (cg-RX-API-DMAC7.html)
JP (1) JP6745873B2 (cg-RX-API-DMAC7.html)
CN (1) CN108289932A (cg-RX-API-DMAC7.html)
ES (1) ES2799515T3 (cg-RX-API-DMAC7.html)
RU (1) RU2726131C2 (cg-RX-API-DMAC7.html)
WO (1) WO2016190780A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016190780A1 (en) 2015-05-22 2016-12-01 Dmitry Dmitrievich Genkin Extracellular dna as a therapeutic target in neurodegeneration
WO2018197547A1 (en) * 2017-04-25 2018-11-01 Lipoxen Technologies Limited Methods of treating diseases related to net formation with parenteral administration of polysialylated dnase i
US12274720B2 (en) 2017-05-24 2025-04-15 Viktor Veniaminovich Tets Methods for treating and preventing diseases
EP3685165B1 (en) 2017-09-18 2022-04-20 Santersus AG Method and device for purification of blood from circulating cell free dna
JP2021510539A (ja) 2018-01-16 2021-04-30 シーエルエス セラピューティクス リミテッドＣＬＳ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ デオキシリボヌクレアーゼ（ＤＮａｓｅ）活性を有する酵素の肝臓発現による疾患の処置
EP3787638A4 (en) * 2018-04-30 2023-10-18 Tets, Viktor, Veniaminovich Tetz-proteins and prion-like proteins and associated methods
EP3852774A4 (en) 2018-06-29 2022-03-23 Tets, Viktor, Veniaminovich METHODS OF DIAGNOSIS AND TREATMENT OF TYPE 1 DIABETES
EP3813555A4 (en) 2018-06-29 2022-03-30 Tets, Viktor, Veniaminovich COMPOSITIONS FOR MODULATION OF INTESTINAL FLORA
CN110129245B (zh) * 2019-07-08 2020-12-04 南京工业大学 一株敲除胞外核酸酶ExeP的谷氨酸棒杆菌及其构建方法与应用
CA3147034A1 (en) * 2019-07-12 2021-01-21 Cls Therapeutics Limited Treatment of diseases associated with protein misfolding by nervous system expression of an enzyme which has a deoxyribonuclease (dnase) activity
EP4119149A1 (en) * 2021-07-15 2023-01-18 Foundation For Research And Technology Hellas Extracellular vesicles comprising a therapeutic cargo
WO2023126672A1 (en) 2021-12-27 2023-07-06 Santersus Ag Method and device for removal of circulating cell free dna

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3224942A (en) 1962-01-15 1965-12-21 Rorer Inc William H Anti-inflammatory, anti-edema and anti-thrombi drug
US3324002A (en) 1962-09-17 1967-06-06 Armour Pharma Anti-inflammatory preparations containing proteolytic enzymes and adrenal glucocorticoids
JPS5826822A (ja) 1981-08-10 1983-02-17 Kaken Pharmaceut Co Ltd 慢性腎炎治療剤
JPS61293927A (ja) 1986-06-18 1986-12-24 Kaken Pharmaceut Co Ltd 肝臓疾患予防治療剤
US4985243A (en) 1988-01-20 1991-01-15 Ml Technology Ventures, L.P. Composition and method for protecting against diseases caused by microorganisms
DE68929551T2 (de) 1988-12-23 2008-03-06 Genentech, Inc., South San Francisco Menschliche DNase
US5464817A (en) 1990-04-11 1995-11-07 Brigham And Women's Hospital Method for reducing the viscosity of pathological mucoid airway contents in the respiratory tract comprising administering actin-binding compounds with or without DNASE I
DE4024530A1 (de) 1990-08-02 1992-02-06 Klinger & Co Dr Verfahren zur bekaempfung von viren
FR2666096B1 (fr) 1990-08-21 1993-12-31 Sfri Sa Nouveau procede de dosage d'acide desoxyribonucleique present en position extracellulaire dans un milieu.
AU2143992A (en) 1991-08-16 1993-03-16 Vical, Inc. Composition and method for treating cystic fibrosis
US5484589A (en) 1992-04-20 1996-01-16 Rufeld, Inc. Anti-viral methods using RNAse and DNAse
NZ299257A (en) 1992-06-08 2000-08-25 Genentech Inc Treating purulent material (eg pulmonary disease) accumulation in patients using deamidated DNase
WO1995000170A1 (en) 1993-06-24 1995-01-05 Rufeld, Inc. Inhibition of human immunodeficiency virus reproduction by deoxyribonuclease i
CH686982A5 (fr) 1993-12-16 1996-08-15 Maurice Stroun Méthode pour le diagnostic de cancers.
RU2099080C1 (ru) 1994-02-11 1997-12-20 Дмитрий Иванович Финько Способ предотвращения развития рака
DE69533128T2 (de) 1994-03-04 2005-06-09 Genentech, Inc., South San Francisco Pharmazeutische akzeptabel dnase zusammensetzung
US5830744A (en) 1995-06-06 1998-11-03 Human Genome Sciences, Inc. Gene encoding human Dnase
US5889153A (en) 1994-05-20 1999-03-30 Hisamitsu Pharmaceutical Co., Inc. Protein or polypeptide, method for producing the same and intermediate compound therefor
JP4118334B2 (ja) 1996-02-05 2008-07-16 ジェネンテック・インコーポレーテッド ヒトｄｎアーゼ
US6156504A (en) 1996-03-15 2000-12-05 The Penn State Research Foundation Detection of extracellular tumor-associated nucleic acid in blood plasma or serum using nucleic acid amplification assays
US6391607B1 (en) 1996-06-14 2002-05-21 Genentech, Inc. Human DNase I hyperactive variants
US5855920A (en) 1996-12-13 1999-01-05 Chein; Edmund Y. M. Total hormone replacement therapy
US6242426B1 (en) 1997-07-25 2001-06-05 Avigen, Inc. Induction of immune response to antigens expressed by recombinant adeno-associated virus
US6455250B1 (en) 1997-12-11 2002-09-24 The Regents Of The University Of California Endonuclease compositions and methods of use
KR100763211B1 (ko) 1998-07-16 2007-10-08 리서치 디벨럽먼트 파운데이션 신규한 ｄｎａ-절단 항종양제
US6465177B1 (en) 1998-10-26 2002-10-15 John Wayne Cancer Institute Detection of loss of heterozygosity in tumor and serum of melanoma patients
WO2000031238A2 (en) 1998-11-25 2000-06-02 Genetica, Inc. Methods and reagents for increasing proliferative capacity and preventing replicative senescence
JP2000229881A (ja) 1999-02-10 2000-08-22 Morinaga Milk Ind Co Ltd 癌疾患の予後改善剤
EP1122306B1 (en) 1999-08-17 2007-08-08 Tanuma, Sei-ichi Novel deoxyribonuclease, gene encoding the same and use thereof
US6428785B1 (en) 1999-10-28 2002-08-06 Immunolytics Inc. Method and composition for treating prostate cancer
UA78486C2 (uk) 1999-12-10 2007-04-10 Хемджен Корпорейшн Композиція для перорального введення птахам та тваринам для лікування або зниження ризику інфекції травного тракту (варіанти), її застосування (варіанти) та спосіб лікування або зниження ризику інфекцій травного тракту (варіанти)
WO2001074905A1 (en) 2000-04-03 2001-10-11 Antisoma Research Limited Compounds for targeting
US6462017B1 (en) 2000-05-01 2002-10-08 Sciclone Pharmaceuticals, Inc. Method of reducing side effects of chemotherapy in cancer patients
RU2202109C1 (ru) 2001-08-03 2003-04-10 Научно-исследовательский институт неврологии РАН Способ выявления степени нарушения реологических свойств крови
RU2207876C1 (ru) 2001-11-08 2003-07-10 Ткаченко Виталий Васильевич Способ комплексно-индивидуализированного воздействия на организм при медленной вирусной инфекции и способ подготовки лабораторного животного для испытания способа такого воздействия
US7402724B2 (en) 2002-01-04 2008-07-22 Mayo Foundation For Medical Education And Research Longevity and PAPP-A
CA2516322C (en) * 2002-02-18 2013-10-15 University Of Southampton Glycosaminoglycan-dnase combination therapy
DE10221194B4 (de) 2002-05-13 2005-02-10 Fryda, Waltraud, Dr.med. Hyaluronidasehaltiges Hautpflegemittel
US20040001817A1 (en) 2002-05-14 2004-01-01 Giampapa Vincent C. Anti-aging nutritional supplement
DE60219809T2 (de) 2002-12-18 2008-01-17 Coy, Johannes F., Dr. Verbindungen und Verfahren zur Nachweiss von Karzinomen und deren Vorstufen
RU2239442C1 (ru) 2003-05-05 2004-11-10 Красноярская государственная медицинская академия Способ профилактики внутриутробных инфекций у детей
RU2269356C2 (ru) 2003-07-14 2006-02-10 Дмитрий Дмитриевич Генкин Способ лечения онкологических заболеваний
AU2003298972A1 (en) 2003-07-14 2005-02-04 Dmitry Dmitrievich Genkin Method for treating oncological, virulent and somatic diseases, method for controlling treatment efficiency, pharmaceutical agents and composition for carrying out said treatment
RU2269359C2 (ru) 2004-03-12 2006-02-10 Дмитрий Дмитриевич Генкин Способ профилактики развития онкологических заболеваний или инфекций, вызываемых бактериями, грибами и простейшими, или атеросклероза, или сахарного диабета, или заболеваний, связанных с реакцией гиперчувствительности замедленного типа, или заболеваний, развивающихся вследствие мутации генов соматических клеток (варианты)
WO2005004904A1 (en) 2003-07-14 2005-01-20 Dmitry Dmitrievich Genkin Method for treating diseases associated with modifications of qualitative and/ quantitative composition of blood extracellular dna (variants)
US8431123B2 (en) 2003-07-14 2013-04-30 Cls Therapeutics Limited Method for treating systemic bacterial, fungal and protozoan infection
US8710012B2 (en) 2003-07-14 2014-04-29 Cls Therapeutics Limited Method for treating oncological diseases
RU2269358C2 (ru) 2003-07-14 2006-02-10 Дмитрий Дмитриевич Генкин Способ лечения генерализованных инфекций, вызываемых бактериями, или заболеваний, вызываемых грибами и простейшими, или атеросклероза, или сахарного диабета, или заболеваний, связанных с реакцией гиперчувствительности замедленного типа, или заболеваний, обусловленных мутациями генов соматических клеток
US8388951B2 (en) 2003-07-14 2013-03-05 Cls Therapeutics Limited Method for treating systemic DNA mutation disease
US8173618B2 (en) * 2003-07-25 2012-05-08 University Of Massachusetts Formulations for reducing neuronal degeneration
RU2239404C1 (ru) 2003-09-17 2004-11-10 Бессонов Дмитрий Михайлович Способ профилактики старения организма человека
RU2267329C2 (ru) 2004-03-12 2006-01-10 Дмитрий Дмитриевич Генкин Способ лечения заболеваний, сопровождающихся изменениями качественного и/или количественного состава внеклеточной днк крови (варианты)
RU2269357C2 (ru) 2004-03-12 2006-02-10 Дмитрий Дмитриевич Генкин Способ замедления наступления болезненных состояний, связанных с увеличением возраста человека
WO2005115444A2 (en) 2004-04-14 2005-12-08 Avirid, Inc. Compositions with modified nucleases targeted to viral nucleic acids and methods of use for prevention and treatment of viral diseases
JP5214252B2 (ja) * 2005-03-03 2013-06-19 イミューノメディクス、インコーポレイテッド ヒト化ｌ２４３抗体
JP3989936B2 (ja) 2005-04-07 2007-10-10 進 須永 抗腫瘍剤及び新規ｄｎアーゼ
EP1880733A4 (en) 2005-04-25 2009-08-12 Genkin Dmitry Dmitrievich METHOD FOR EXTENDING THE LIFE OF A HUMAN AND ANIMALS
KR20080038131A (ko) 2005-07-18 2008-05-02 프로탈릭스 리미티드 생물학적으로 활성인 거대분자의 점막 또는 장관 투여
RU2308968C2 (ru) 2005-07-19 2007-10-27 Дмитрий Дмитриевич Генкин Способ лечения заболеваний человека, сопровождающихся повышенным содержанием дезоксирибонуклеиновой кислоты во внеклеточных пространствах тканей, и лекарственный препарат для его реализации
US20080131497A1 (en) 2006-09-28 2008-06-05 Perkins Walter R Formulations of DNase and Methods of Use Thereof
PL2086642T3 (pl) 2006-10-18 2015-02-27 Periness Ltd DNaza do leczenia męskiej subpłodności
KR20090087095A (ko) 2006-11-28 2009-08-14 드미트리 드미트리에비치 겐킨 조직의 세포외공간에서 증가된 데옥시리보핵산 함량과 관련된 인간 질병을 치료하는 방법 및 이 방법을 수행하기 위한 약학 제제
GB0922006D0 (en) 2009-12-17 2010-02-03 Genome Res Ltd Diagnostic
CA2814962A1 (en) * 2010-12-02 2012-06-07 Immunomedics, Inc. In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
WO2012075506A2 (en) 2010-12-03 2012-06-07 Beth Israel Deaconess Medical Center, Inc. Methods for predicting and treating infection-induced illnesses and predicting the severity of infection-induced illnesses
WO2013114373A1 (en) 2012-02-01 2013-08-08 Protalix Ltd. Inhalable liquid formulations of dnase i
AU2013221212B2 (en) 2012-02-17 2018-08-09 The Children's Hospital Of Philadelphia AAV vector compositions and methods for gene transfer to cells, organs and tissues
MX359291B (es) 2012-08-03 2018-09-24 Ferring Bv Adn libre de celulas como objetivo terapeutico para la infertilidad femenina y marcador de diagnostico.
CN116574158A (zh) 2013-10-11 2023-08-11 马萨诸塞眼科耳科诊所 预测祖先病毒序列的方法及其用途
EP3119896B1 (en) 2014-03-21 2022-03-23 The Sydney Children's Hospitals Network (Randwick and Westmead) Stable gene transfer to proliferating cells
EP4344741A3 (en) 2014-11-21 2024-08-28 The University of North Carolina at Chapel Hill Aav vectors targeted to the central nervous system
WO2016190780A1 (en) 2015-05-22 2016-12-01 Dmitry Dmitrievich Genkin Extracellular dna as a therapeutic target in neurodegeneration
KR20210005994A (ko) 2015-11-05 2021-01-15 뱀부 테라퓨틱스 인코포레이티드 유전자 치료를 위한 변형된 프리드라이히 운동실조증 유전자 및 벡터
EP3420077A4 (en) 2016-02-25 2019-12-25 Agenovir Corporation VIRAL AND ONCOVIRAL NUCLEASE TREATMENT

Also Published As

Publication number Publication date
JP2018520208A (ja) 2018-07-26
EP3297657A4 (en) 2018-11-14
RU2726131C2 (ru) 2020-07-09
EP3297657A1 (en) 2018-03-28
EP3297657B1 (en) 2020-03-25
US11701410B2 (en) 2023-07-18
US20180360925A1 (en) 2018-12-20
RU2017145051A (ru) 2019-06-24
CN108289932A (zh) 2018-07-17
WO2016190780A1 (en) 2016-12-01
ES2799515T3 (es) 2020-12-18
RU2017145051A3 (cg-RX-API-DMAC7.html) 2019-06-24

Similar Documents

Publication Publication Date Title
JP6745873B2 (ja) 神経変性における治療標的としての細胞外ｄｎａ
Xie et al. Magnolol alleviates Alzheimer's disease-like pathology in transgenic C. elegans by promoting microglia phagocytosis and the degradation of beta-amyloid through activation of PPAR-γ
Hwang et al. Microglia signaling as a target of donepezil
CN113164508B (zh) 与神经保护剂组合的sarm1抑制剂
CN102548571B (zh) 用于预防和治疗脑部疾病和疾病状态的组合物和方法
Deegan et al. Venglustat, an orally administered glucosylceramide synthase inhibitor: Assessment over 3 years in adult males with classic Fabry disease in an open-label phase 2 study and its extension study
Yu et al. Prednisone alleviates demyelination through regulation of the NLRP3 inflammasome in a C57BL/6 mouse model of cuprizone-induced demyelination
US20220072019A1 (en) Inhibitors of sarm1 in combination with nad+ or a nad+ precursor
US20230242909A1 (en) Methods and compositions for neuroprotection
Lin et al. Aerobic exercise improves type 2 diabetes mellitus‐related cognitive impairment by inhibiting JAK2/STAT3 and enhancing AMPK/SIRT1 pathways in mice
US10537607B2 (en) Treatment of autoimmune and/or inflammatory disease using novel caveolin modulators
Korabecny et al. Pharmacotherapy of Alzheimer’s disease: current state and future perspectives
Ketata et al. From pathological mechanisms in Krabbe disease to cutting‐edge therapy: A comprehensive review
CN120310791A (zh) 靶向α-突触核蛋白的反义寡核苷酸及其用途
US20240100076A1 (en) Methods and compositions for treating neurodegenerative diseases
CN100525764C (zh) 吡唑并吡啶在制备治疗认知缺陷的药物中的应用
JP4619666B2 (ja) 医薬組成物
Ishigaki et al. Fukuyama congenital muscular dystrophy: clinical features and therapeutic advances
AU2024260719A1 (en) Mivelsiran compositions and methods of use thereof
Croasdell Alzheimer
Wang et al. A Double-Edged Sword: Exploring the Neuroprotective/Damaging Mechanisms of Complement Activation in Alzheimer's Disease
Parsons et al. P4-362 Statins reduce β-amyloid production but increase its release from the cell
CN121285631A (zh) 米韦西兰组合物及其使用方法
CN118593706A (zh) 通过调节Endoglin治疗痴呆的方法
Zhang et al. P4-363 Chinese herb component SSY-P3 protects against abnormality in animal models of Alzheimer's disease

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190513

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190513

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190805

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200325

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200331

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200629

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200707

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200804

R150 Certificate of patent or registration of utility model

Ref document number: 6745873

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250